Valion Bio, Inc. (VBIO) is the subject of an amended Schedule 13G filing in which a group of investors led by 3i, LP reports beneficial ownership of 132,671 shares of common stock, equal to 9.99% of the class based on 1,285,626 shares outstanding as of August 24, 2026.
The position consists of 90,252 shares of common stock held by 3i, LP plus up to 42,419 additional shares issuable from warrants, a senior secured convertible note, and Series B and Series C Convertible Preferred Stock, all subject to a 9.99% beneficial ownership limitation. The investors state they no longer hold VBIO securities with a purpose or effect of changing or influencing control, so their Schedule 13D has been amended back to a 13G. All share figures reflect Valion Bio’s 1-for-25 reverse stock split effective August 31, 2026.
Valion Bio, Inc. (VBIO) received Amendment No. 7 to a Schedule 13D from 3i, LP, 3i Management LLC and Maier J. Tarlow, updating their ownership after recent transactions and a reverse stock split. The reporting group now has beneficial ownership of 132,671 shares of Common Stock, representing 9.9% of the outstanding common stock, based on 1,285,626 shares outstanding as of August 24, 2026.
The 132,671 shares include 90,252 shares of common stock held by 3i, LP and 42,419 shares issuable upon a combination of warrant exercises and conversions of a senior secured convertible note and Series B and Series C Convertible Preferred Stock, all subject to a 9.99% beneficial ownership limitation. Tumim Stone Capital, LLC now reports 0 shares beneficially owned. All share figures reflect Valion Bio’s 1-for-25 reverse stock split effective August 31, 2026.
Valion Bio, Inc. (VBIO) received additional financing-linked securities from 3i, LP and now has 3i and its affiliates reporting beneficial ownership of 133,005 shares of Common Stock, or 9.9% of the class, based on 1,285,626 shares outstanding as of August 24, 2026.
Beneficial ownership includes 87,248 common shares held by 3i, LP and 45,757 shares issuable from a senior secured convertible note, Series B and Series C Convertible Preferred Stock and warrants, each subject to a 9.99% beneficial ownership limitation. On August 31, 2026, 3i, LP acquired 100 Series B Preferred shares, 7,637 Series C Preferred shares, and warrants for 1,057,046 common shares at an exercise price of $3.62 per share for an aggregate purchase price of $7,737,000, primarily through setoff of amounts owed and including $1,500,000 in cash to Valion Bio. The disclosure also notes Valion Bio’s previously effected 1-for-25 reverse stock split on August 31, 2026.
Valion Bio, Inc. (VBIO) entered into a new letter agreement with 3i, LP under existing preferred stock purchase arrangements. Valion will issue 100 Series B Non-Voting Convertible Preferred Shares, 7,637 Series C Non-Voting Convertible Preferred Shares, Series B Warrants for 3,077 common shares at $3.62, and Series C Warrants for 1,053,969 common shares at $3.62, for an aggregate purchase price of $7,737,000.
Of this amount, $6,137,000 will be retained by 3i to satisfy overdue cash true-up payments, $100,000 will cover 3i’s legal fees, and $1,500,000 will be paid to Valion in cash. The warrant share counts and exercise prices reflect a 1-for-25 reverse stock split effective at 12:01 a.m. Eastern Time on August 31, 2026. Valion agreed to file and maintain a resale registration statement for the shares underlying the new preferred stock and warrants.
Separately, Lisa Wolf, already Chief Financial Officer, has been appointed President and Chief Operating Officer and will assume executive leadership following the departure of former CEO Michael K. Handley. The company also added two new directors, Jared Malbin, with extensive capital-markets and regulatory experience, and Thomas Jensen, CEO of Allarity Therapeutics with biotechnology and oncology expertise.
Valion Bio, Inc. (VBIO) is the subject of this Amendment No. 5 to a Schedule 13D, updating the ownership position of investment entities led by 3i, LP and related reporting persons. They report beneficial ownership of 3,334,139 shares of common stock, representing 9.9% of Valion Bio’s common stock outstanding as of August 24, 2026.
The position includes 2,100,000 shares of common stock currently held and 1,234,139 shares issuable upon exercises or conversions of warrants, a senior secured convertible note, and Series B and Series C Convertible Preferred Stock, all subject to a 9.99% beneficial ownership limitation (Blocker). Tumim Stone Capital, LLC now reports 0 beneficial ownership. The amendment also adds Exhibit 9 listing additional transactions.
Valion Bio, Inc. (VBIO) announced that its board and stockholders have approved a 1-for-25 reverse stock split of its common stock. The reverse split will become effective on August 31, 2026 at 12:01 a.m. Eastern Time, after which the stock will trade on a split-adjusted basis on the Nasdaq Capital Market under the symbol “VBIO” with a new CUSIP 918942202.
The stated purpose is to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement before the compliance period ending September 15, 2026. Every 25 existing shares will be combined into one share, with no cash paid for fractional shares; any fractional amounts will be rounded up to the nearest whole share. Authorized share counts and par value remain unchanged, and each stockholder’s percentage ownership and voting power are expected to remain materially the same aside from rounding effects.
Valion Bio, Inc. (VBIO) is the subject of this Amendment No. 4 to a Schedule 13D, updating the ownership position of 3i, LP, 3i Management LLC and Maier J. Tarlow. These reporting persons now report beneficial ownership of 2,102,780 shares of common stock, representing 9.9% of Valion Bio’s common stock.
The percentage is based on 20,913,373 shares outstanding, which includes multiple blocks of common stock issued to 3i, LP between July 19 and August 20, 2026 upon conversions of Series B and Series C Convertible Preferred Stock. Beneficial ownership comprises 1,967,298 shares held by 3i, LP and 135,482 shares issuable from warrants, a senior secured convertible note and preferred shares, each subject to a 9.99% beneficial ownership limitation Blocker. Tumim Stone Capital, LLC now reports 0 shares beneficially owned. The amendment also updates Item 5 and adds Exhibit 8 for additional transactions.
Valion Bio, Inc. (VBIO) reported final voting results from its August 14, 2026 Special Meeting of Stockholders. Common stock was the only voting class, with 4,151,259 shares outstanding as of the July 7, 2026 record date, and 2,001,335 shares present, representing approximately 48.21% and establishing a quorum.
Stockholders approved granting the board of directors discretionary authority to amend the certificate of incorporation to implement a reverse stock split of the common stock at a ratio between 1-for-5 and 1-for-50, to be selected by the board within twelve months of the meeting, without further stockholder approval. Stockholders also approved a proposal authorizing potential adjournment to solicit additional proxies, although the meeting was not adjourned because the reverse split authority had already been approved.
Valion Bio, Inc. (VBIO) is the subject of this amended Schedule 13D, which updates the holdings and financing arrangements of 3i, LP and related reporting persons. 3i, LP, 3i Management LLC and Maier J. Tarlow each report beneficial ownership of 2,050,200 shares of common stock, representing 9.9% of the outstanding common stock of Valion Bio, Inc. based on 18,892,969 shares outstanding. Tumim Stone Capital, LLC now reports 0% beneficial ownership.
The 2,050,200 shares consist of 420,641 common shares held for 3i, LP and 1,629,559 shares issuable in any combination upon exercises of warrants, and conversions of a senior secured convertible note and Series B and Series C preferred stock, each subject to a 9.99% beneficial ownership limitation Blocker. This structure caps how many shares 3i, LP can hold at any time.
On August 17, 2026, Valion Bio, Inc. and 3i, LP entered into a letter agreement under which the company issued 1,500 shares of Series B Preferred Stock at $1,000 per share and granted warrants to purchase 1,153,847 common shares at an initial exercise price of $0.23708 per share, for an aggregate purchase price of $1,500,000. The parties state they are negotiating in good faith regarding additional funding tranches but have no definitive agreements in place.